Triventures is a global venture capital firm that invests in startups led by exceptional entrepreneurs. The fund identifies cross-industry breakthroughs that converge the best in class in health and non-health technologies such as insurtech and fintech for healthcare, e-commerce and cyber for healthcare, community-driven genomics, health data marketplaces, and more. Triventures’ team is comprised of key opinion leaders in healthcare, entrepreneurship, venturing and corporate business development and has decades of accumulated industry experience and relationships. Triventures was founded in 2010 and is headquartered in Herzliya, Tel Aviv, Israel with offices in California, U.S.

Triventures

Established in 2015, Quark Venture Inc. is a venture capital investment firm, headquartered in Vancouver, Canada, and is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects.

Quark Venture

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

Pontifax

BioStar Ventures is a venture capital company that offers private equity investment services to firms in the medical device technology services industries. It was founded in 2003 by Louis Cannon and is based in Michigan.

BioStar Capital

Venutre Capital Fund that invests European entrepreneurs’ money in advanced technology solutions for fast growing B2B markets leveraging on a unique due diligence strategy and a proven proprietary deal sourcing

Planven Entrepreneur Ventures

Corundum Open Innovations is a venture capital firm that invests in ICT and life sciences companies and funds. It provides access to the high-tech ecosystem and hands-on business development for investors and portfolio companies. The firm's portfolio companies enjoy market insights and go–to–market strategies and introductions to top talent and key business partners. The Herzelia, Tel Aviv-headquartered firm was launched in 2015.

Corundum Open Innovations

Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.

Deerfield

CathWorks

CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize pci therapy decisions and elevate coronary angiography from visual assessment to an objective FFRangio-based decision-making tool for physicians.

CathWorks is a medical technology company that has developed the FFRangio System, an innovative solution for diagnosing and assessing coronary artery disease (CAD). Founded in 2013, the company is headquartered in Kfar Saba, Israel, with additional operations in Irvine, California. The FFRangio System combines artificial intelligence and advanced computational science to obtain quick and reliable fractional flow reserve (FFR) values from routine angiograms. Unlike traditional FFR methods, which require invasive pressure wires and drug stimulation, the FFRangio System provides a non-invasive, wire-free, and drug-free intraprocedural physiological assessment for the entire coronary tree in just five minutes. This technology eliminates the need for invasive pressure wires and hyperemic agents, potentially improving patient comfort and streamlining the diagnostic process. Clinical data published in the Journal of the American College of Cardiology: Cardiovascular Interventions demonstrated a diagnostic accuracy of 93%, sensitivity of 91%, and specificity of 94%. In July 2022, CathWorks entered into a strategic partnership with Medtronic, which included a USD 75 million investment and co-promotion agreement for the FFRangio System in the US, Europe, and Japan.

CathWorks FFRangio System

Medtronic enters partnership with CathWorks with $585m buyout option

Fourth Generation CathWorks FFRangio® System Receives Regulatory Approval in Japan

Medtronic partners with CathWorks to work on CAD diagnosis and treatment

Promotion Agreement With CathWorks, With Path Toward Acquisition

Medtronic announces co-promotion agreement with CathWorks, with path toward acquisition

Medtronic partners with CathWorks with option to acquire down the line

CathWorks Announces First Patient Enrolled in Global ALL-RISE Study

Medtronic lands option to buy artery disease player CathWorks for up to $585M

Medtronic investing $75 million in CathWorks, can acquire digital health company for

CathWorks FFRangio® System: A New Era in Coronary Physiology(TCT Boston 2022)

CathWorks Announces Key Events for ACC 2023

ALL-RISE study of CathWorks FFRangio system enrols first patient

promotion agreement with CathWorks

CathWorks’ Feher Believes in ‘Revolutionary Technology’

CathWorks, Medtronic Partner on Heart Technology

CSSMCW Adopts Innovative CathWorks FFRangio System

Medtronic Partners with CathWorks, with Option to Acquire in the Future

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

CathWorks Announces Key Events for TCT 2024

Medtronic

Medtronic has entered into a strategic partnership agreement with CathWorks which aims to transform how coronary artery disease (CAD) is diagnosed and treated.

CathWorks is a medical technology company that has developed the FFRangio System, an innovative solution for diagnosing and assessing coronary artery disease (CAD). Founded in 2013, the company is headquartered in Kfar Saba, Israel, with additional operations in Irvine, California. The FFRangio System combines artificial intelligence and advanced computational science to obtain quick and reliable fractional flow reserve (FFR) values from routine angiograms. Unlike traditional FFR methods, which require invasive pressure wires and drug stimulation, the FFRangio System provides a non-invasive, wire-free, and drug-free intraprocedural physiological assessment for the entire coronary tree in just five minutes. This technology eliminates the need for invasive pressure wires and hyperemic agents, potentially improving patient comfort and streamlining the diagnostic process. Clinical data published in the Journal of the American College of Cardiology: Cardiovascular Interventions demonstrated a diagnostic accuracy of 93%, sensitivity of 91%, and specificity of 94%. In July 2022, CathWorks entered into a strategic partnership with Medtronic, which included a USD 75 million investment and co-promotion agreement for the FFRangio System in the US, Europe, and Japan.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

CathWorks

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless